{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:51:49Z","timestamp":1781189509823,"version":"3.54.1"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ranolazine is a highly effective inhibitor of the late sodium current and has been received approval from the FDA in 2006 for the treatment of chronic angina. To date, nearly 2000 papers have been published on it. It has demonstrated therapeutic potential in various fields, but uncertainties regarding its efficacy, safety risks, and limitations in expanding indications have hindered its clinical application. Therefore, we believe that the current period is the best time to conduct bibliometric analysis to overcome existing challenges and optimize interdisciplinary strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched and downloaded the papers in the Science Citation Index Expanded database of the Web of Science Core Collection on September 1, 2025. Microsoft Excel was applied to organize the data, WeiShengXin, CiteSpace and VOS viewer were used for data analysis and visualization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 1121 papers were included for follow-up research. The USA is the most productive country in this field and serves as a central hub for global cooperation and exchange. Gilead Sciences is the institution with the highest output in this field. Professor Belardinelli, L and Professor Chaitman, BR are the most influential authors in this field. The keywords \u201cefficacy,\u201d \u201cventricular arrhythmias,\u201d \u201cimpact\u201d and \u201cchannels\u201d still have a strong influence at present.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Currently, the research focus in this field primarily centers on 3 key aspects: the anti-angina effect, the electrophysiological characteristics and anti-arrhythmic effect and other effects of ranolazine. The future research direction in this field is likely to focus on the neuroprotective effect of ranolazine, its antitumor metastasis effect and its effect on atrial fibrillation and diabetes patients on the basis of maintaining the current research focus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045694","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T21:00:09Z","timestamp":1763154009000},"page":"e45694","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Development trend analysis of ranolazine, based on bibliometrics"],"prefix":"10.1097","volume":"104","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1490-2379","authenticated-orcid":false,"given":"Bingju","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251121","first-page":"131","article-title":"Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina-pectoris patients treated with beta-blocker or diltiazem.","volume":"20","author":"Cocco","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"R2-20251121","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/jmcc.1996.0032","article-title":"Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism.","volume":"28","author":"Clarke","year":"1996","journal-title":"J Mol Cell Cardiol"},{"key":"R3-20251121","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.93.1.135","article-title":"Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.","volume":"93","author":"McCormack","year":"1996","journal-title":"Circulation"},{"key":"R4-20251121","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1476-5381.1993.tb13637.x","article-title":"Protective effects of ranolazine in guinea-pig hearts during low-flow ischemia and their association with increases in active pyruvate-dehydrogenase.","volume":"109","author":"Clarke","year":"1993","journal-title":"Br J Pharmacol"},{"key":"R5-20251121","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/cvr\/28.8.1231","article-title":"Cardioprotective effects of ranolazine (rs-43285) in the isolated-perfused rabbit heart.","volume":"28","author":"Gralinski","year":"1994","journal-title":"Cardiovasc Res"},{"key":"R6-20251121","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/01.CIR.90.2.726","article-title":"Double-blind efficacy and safety study of a novel antiischemic agent, ranolazine, versus placebo in patients with chronic stable angina-pectoris.","volume":"90","author":"Thadani","year":"1994","journal-title":"Circulation"},{"key":"R7-20251121","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0002-9149(99)00190-3","article-title":"A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents.","volume":"84","author":"Pepine","year":"1999","journal-title":"Am J Cardiol"},{"key":"R8-20251121","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina \u2013 a randomized controlled trial.","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"R9-20251121","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R10-20251121","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-2999(01)00920-7","article-title":"Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.","volume":"418","author":"Zacharowski","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"R11-20251121","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1054\/jcaf.2002.129232","article-title":"Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.","volume":"8","author":"Sabbah","year":"2002","journal-title":"J Card Fail"},{"key":"R12-20251121","doi-asserted-by":"crossref","first-page":"iv6","DOI":"10.1136\/hrt.2005.078790","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine.","volume":"92","author":"Belardinelli","year":"2006","journal-title":"Heart"},{"key":"R13-20251121","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00005344-200408000-00008","article-title":"Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.","volume":"44","author":"Song","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"R14-20251121","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1124\/jpet.104.066100","article-title":"Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.","volume":"310","author":"Wu","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20251121","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","article-title":"Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with Non-ST-Segment-Elevation acute coronary syndrome \u2013 thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial.","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"R16-20251121","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.hrthm.2011.03.045","article-title":"Electrophysiologic basis for the antiarrhythmic actions of ranolazine.","volume":"8","author":"Antzelevitch","year":"2011","journal-title":"Heart Rhythm"},{"key":"R17-20251121","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(10)60096-7","article-title":"New antiarrhythmic drugs for treatment of atrial fibrillation.","volume":"375","author":"Dobrev","year":"2010","journal-title":"Lancet"},{"key":"R18-20251121","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jacc.2009.12.055","article-title":"Altered Na+ currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium.","volume":"55","author":"Sossalla","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R19-20251121","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2008.03.006","article-title":"Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts \u2013 role of late sodium current and intracellular ion accumulation.","volume":"45","author":"Sossalla","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"R20-20251121","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1540-8167.2008.01246.x","article-title":"Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.","volume":"19","author":"Moss","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R21-20251121","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.bjp.0706709","article-title":"Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.","volume":"148","author":"Fredj","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R22-20251121","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","article-title":"Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.","volume":"112","author":"Villano","year":"2013","journal-title":"Am J Cardiol"},{"key":"R23-20251121","doi-asserted-by":"crossref","first-page":"1267675","DOI":"10.3389\/fnins.2023.1267675","article-title":"Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia.","volume":"17","author":"Samir","year":"2024","journal-title":"Front Neurosci"},{"key":"R24-20251121","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MCA.0000000000001347","article-title":"Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial.","volume":"35","author":"Yusuf","year":"2024","journal-title":"Coron Artery Dis"},{"key":"R25-20251121","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41416-024-02622-w","article-title":"Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels.","volume":"130","author":"Djamgoz","year":"2024","journal-title":"Br J Cancer"},{"key":"R26-20251121","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0165551507087238","article-title":"Bibliometrics to webometrics.","volume":"34","author":"Thelwall","year":"2008","journal-title":"J Inf Sci"},{"key":"R27-20251121","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF02016680","article-title":"Toward a definition of bibliometrics.","volume":"12","author":"Broadus","year":"1987","journal-title":"Scientometrics"},{"key":"R28-20251121","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/aris.1440360102","article-title":"Scholarly communication and bibliometrics.","volume":"36","author":"Borgman","year":"2002","journal-title":"Annu Rev Inform Sci Technol"},{"key":"R29-20251121","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.hrthm.2024.01.032","article-title":"Bibliometric analysis of atrial fibrillation and ion channels.","volume":"21","author":"Zhu","year":"2024","journal-title":"Heart Rhythm"},{"key":"R30-20251121","doi-asserted-by":"crossref","first-page":"16569","DOI":"10.1073\/pnas.0507655102","article-title":"An index to quantify an individual\u2019s scientific research output.","volume":"102","author":"Hirsch","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R31-20251121","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jama.295.1.90","article-title":"The history and meaning of the journal impact factor.","volume":"295","author":"Garfield","year":"2006","journal-title":"JAMA"},{"key":"R32-20251121","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping.","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"R33-20251121","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature.","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"R34-20251121","doi-asserted-by":"crossref","first-page":"16812","DOI":"10.1002\/jcp.28350","article-title":"A review on coronary artery disease, its risk factors, and therapeutics.","volume":"234","author":"Malakar","year":"2019","journal-title":"J Cell Physiol"},{"key":"R35-20251121","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.cell.2018.11.042","article-title":"A platform for generation of chamber-specific cardiac tissues and disease modeling.","volume":"176","author":"Zhao","year":"2019","journal-title":"Cell"},{"key":"R36-20251121","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.","volume":"81","author":"Crumb","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R37-20251121","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin.","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"R38-20251121","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jcmg.2022.12.015","article-title":"Myocardial perfusion PET for the detection and reporting of coronary microvascular dysfunction: a JACC: cardiovascular imaging expert panel statement.","volume":"16","author":"Schindler","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"R39-20251121","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","article-title":"Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"R40-20251121","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes \u2013 the MERLIN-TIMI 36 randomized trial.","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"R41-20251121","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC).","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"R42-20251121","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1007\/s00210-024-03746-9","article-title":"Ranolazine effectively improves clinical symptoms in patients with slow flow coronary arteries: a randomized, double-blind, placebo-controlled clinical trial.","volume":"398","author":"Shahri","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R43-20251121","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1016\/j.hrthm.2025.03.1997","article-title":"The modernized classification of cardiac antiarrhythmic drugs: its application to clinical practice.","volume":"22","author":"Lei","year":"2025","journal-title":"Heart Rhythm"},{"key":"R44-20251121","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.hrthm.2009.07.042","article-title":"Use-dependent block of cardiac late Na+ current by ranolazine.","volume":"6","author":"Rajamani","year":"2009","journal-title":"Heart Rhythm"},{"key":"R45-20251121","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.112.198887","article-title":"A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.","volume":"344","author":"Belardinelli","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"R46-20251121","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/CIRCEP.115.002856","article-title":"The HARMONY trial combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism.","volume":"8","author":"Reiffel","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R47-20251121","doi-asserted-by":"crossref","first-page":"e003565","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","article-title":"Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy.","volume":"10","author":"Coppini","year":"2017","journal-title":"Circ Heart Fail"},{"key":"R48-20251121","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1111\/bph.14223","article-title":"Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.","volume":"175","author":"Ferrantini","year":"2018","journal-title":"Br J Pharmacol"},{"key":"R49-20251121","doi-asserted-by":"crossref","first-page":"e004124","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy the RESTYLE-HCM randomized, double-blind, placebo-controlled study.","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"R50-20251121","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions.","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"key":"R51-20251121","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"R52-20251121","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina.","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R53-20251121","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine \u2013 the ERICA (efficacy of ranolazine in chronic angina) trial.","volume":"48","author":"Stone","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R54-20251121","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","article-title":"Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.","volume":"4","author":"Mehta","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"R55-20251121","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjms.2023.12.001","article-title":"Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.","volume":"367","author":"Manolis","year":"2024","journal-title":"Am J Med Sci"},{"key":"R56-20251121","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/jcm13061672","article-title":"Real-world data from the use of ranolazine in patients with stable angina pectoris: the RANGER study.","volume":"13","author":"Olympios","year":"2024","journal-title":"J Clin Med"},{"key":"R57-20251121","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1540-8159.2008.01083.x","article-title":"Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report.","volume":"31","author":"Murdock","year":"2008","journal-title":"Pacing Clin Electrophysiol"},{"key":"R58-20251121","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jacc.2010.07.045","article-title":"Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine.","volume":"57","author":"Morita","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R59-20251121","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2011.04.017","article-title":"Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting.","volume":"108","author":"Miles","year":"2011","journal-title":"Am J Cardiol"},{"key":"R60-20251121","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1540-8159.2011.03298.x","article-title":"The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series.","volume":"35","author":"Murdock","year":"2012","journal-title":"Pacing Clin Electrophysiol"},{"key":"R61-20251121","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jacc.2010.08.600","article-title":"Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.","volume":"56","author":"Burashnikov","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R62-20251121","doi-asserted-by":"crossref","first-page":"118306","DOI":"10.1016\/j.lfs.2020.118306","article-title":"Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1\/NRG1 pathway.","volume":"261","author":"Chen","year":"2020","journal-title":"Life Sci"},{"key":"R63-20251121","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","article-title":"Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.","volume":"133","author":"Sossalla","year":"2012","journal-title":"Pharmacol Ther"},{"key":"R64-20251121","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/jpet.110.176396","article-title":"Ranolazine increases \u03b2-Cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice.","volume":"337","author":"Ning","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R65-20251121","doi-asserted-by":"crossref","first-page":"119525","DOI":"10.1016\/j.atherosclerosis.2025.119525","article-title":"Ranolazine ameliorates palmitic acid-induced insulin resistance in HL-1 cardiomyocytes by CA2+\/ CAMKII modulation: an in vitro investigation and population-based cohort study.","volume":"407","author":"Liu","year":"2025","journal-title":"Atherosclerosis"},{"key":"R66-20251121","doi-asserted-by":"crossref","first-page":"e0150619","DOI":"10.1371\/journal.pone.0150619","article-title":"Effects of ranolazine on astrocytes and neurons in primary culture.","volume":"11","author":"Aldasoro","year":"2016","journal-title":"PLoS One"},{"key":"R67-20251121","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/j.1476-5381.2010.00976.x","article-title":"Ranolazine selectively blocks persistent current evoked by epilepsy-associated NaV1.1 mutations.","volume":"161","author":"Kahlig","year":"2010","journal-title":"Br J Pharmacol"},{"key":"R68-20251121","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bph.12150","article-title":"Effects of the antianginal drug, ranolazine, on the brain sodium channel NaV1.2 and its modulation by extracellular protons.","volume":"169","author":"Peters","year":"2013","journal-title":"Br J Pharmacol"},{"key":"R69-20251121","doi-asserted-by":"crossref","first-page":"16160","DOI":"10.3390\/ijms232416160","article-title":"Ranolazine attenuates brain inflammation in a rat model of type 2 diabetes.","volume":"23","author":"Cassano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R70-20251121","first-page":"2953","article-title":"Ranolazine exhibits anti-inflammatory and antioxidant activities in H9c2 cardiomyocytes.","volume":"27","author":"Dogan","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R71-20251121","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bcpt.13417","article-title":"Riluzole: anti-invasive effects on rat prostate cancer cells under normoxic and hypoxic conditions.","volume":"127","author":"Rizaner","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R72-20251121","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1476-4598-13-264","article-title":"Ranolazine inhibits NaV1.5-mediated breast cancer cell invasiveness and lung colonization.","volume":"13","author":"Driffort","year":"2014","journal-title":"Mol Cancer"},{"key":"R73-20251121","doi-asserted-by":"crossref","first-page":"9660","DOI":"10.3390\/ijms21249660","article-title":"Targeting fat oxidation in mouse prostate cancer decreases tumor growth and stimulates anti-cancer immunity.","volume":"21","author":"Guth","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R74-20251121","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jid.2022.08.038","article-title":"The regulators of peroxisomal acyl-carnitine shuttle CROT and CRAT promote metastasis in melanoma.","volume":"143","author":"Lasheras-Otero","year":"2023","journal-title":"J Invest Dermatol"},{"key":"R75-20251121","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3390\/biomedicines12081669","article-title":"The role of ranolazine in the treatment of ventricular tachycardia and atrial fibrillation: a narrative review of the clinical evidence.","volume":"12","author":"Murai","year":"2024","journal-title":"Biomedicines"},{"key":"R76-20251121","doi-asserted-by":"crossref","first-page":"21563","DOI":"10.1038\/s41598-025-08099-8","article-title":"Effects of ranolazine on angiogenesis and oxidant-antioxidant balance: an in vivo experimental model study.","volume":"15","author":"Kayan","year":"2025","journal-title":"Sci Rep"},{"key":"R77-20251121","doi-asserted-by":"crossref","first-page":"176744","DOI":"10.1016\/j.ejphar.2024.176744","article-title":"Ranolazine ameliorates T1DM-induced testicular dysfunction in rats; role of NF-\u03baB\/TXNIP\/GSDMD-N\/IL-18\/Beclin-1 \u03ba B\/TXNIP\/GSDMD-N\/IL-18\/Beclin-1 signaling pathway.","volume":"977","author":"Samaha","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"R78-20251121","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.3390\/jcm13174985","article-title":"Ranolazine unveiled: rediscovering an old solution in a new light.","volume":"13","author":"De Santis","year":"2024","journal-title":"J Clin Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:00:29Z","timestamp":1763766029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":78,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045694","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"2024-08-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}